Wegovy vs Mounjaro: Uses, Results, Forms and Side Effects
Compare Wegovy and Mounjaro by ingredient, receptor activity, current forms, U.S. and U.K. uses, direct evidence and safety limits.
Wegovy vs Mounjaro
Wegovy contains semaglutide and acts at the GLP-1 receptor; Mounjaro contains tirzepatide and acts at GIP and GLP-1 receptors. They are not interchangeable. In the United States, current Wegovy and Mounjaro labels serve different product-specific purposes, while the U.K. authorizes both brands for weight management in eligible people. SURMOUNT-5 directly compared selected injectable tirzepatide and semaglutide regimens in adults with obesity without diabetes, not every current form, brand claim or individual treatment choice.
An evidence-first comparison sequence
The search terms look like one worldwide contest, but the useful answer has two layers: an exact country-and-brand comparison, then a trial comparison that keeps formulation, population, doses studied, duration and funding visible.
Choose the market before the medicine
In the U.S., Mounjaro is a type 2 diabetes brand; in the U.K., Mounjaro is also licensed for weight management under local criteria. Wegovy forms and uses also change over time and by market.
Separate molecule, receptor and form
Wegovy is semaglutide with GLP-1 receptor activity and current injection and tablet forms in the U.S.; Mounjaro is injectable tirzepatide with GIP and GLP-1 receptor activity.
Keep SURMOUNT-5 inside its protocol
The 72-week open-label trial studied 751 adults with obesity without type 2 diabetes using maximum tolerated weekly injectable regimens. It does not cover children, diabetes, oral Wegovy or every outcome claim.
Return the choice to clinical care
The prescriber must connect indication, health history, other medicines, warnings, monitoring, tolerability, pregnancy context, supply and cost to the exact local product.
The bars organize comparison priority only. They are not dose rankings, efficacy scores, safety ratings, switching instructions or personal-result forecasts.
Why brand, molecule and trial need separate rows
Wegovy contains semaglutide, a GLP-1 receptor agonist. Mounjaro contains tirzepatide, which activates GIP and GLP-1 receptors. Receptor count is a pharmacology difference, not an automatic suitability score.
Brand meaning depends on market. The current U.S. Mounjaro label addresses type 2 diabetes, while U.S. weight-management tirzepatide has a different brand. U.K. authorities describe Mounjaro and Wegovy as licensed weight-management options under local criteria. Wegovy now also has oral forms in the U.S. and U.K., so a two-pen summary is incomplete.
SURMOUNT-5 is valuable direct evidence, but it stays attached to adults with obesity without diabetes, weekly injectable regimens, maximum tolerated protocol doses, 72 weeks, an open-label design and industry funding. It cannot predict one person's response or supply instructions for changing products.
Deeper visual interpretation
A fair comparison starts by asking whether the search means U.S. brands, U.K. weight-management products or the molecules studied in SURMOUNT-5. Those are related but not identical questions.
| Question | Wegovy | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Receptor activity | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist |
| Current U.S. form set | Injection and tablets | Injection |
| Current U.S. brand context | Product-specific weight, cardiovascular and MASH indications in defined populations | Glycemic control in adults and children 10 years and older with type 2 diabetes |
| U.K. weight context | Licensed for weight management under local criteria; injection and tablet authorizations are version-specific | Licensed for weight management and type 2 diabetes under local criteria |
| Protocol element | Included | Boundary |
|---|---|---|
| Population | 751 adults with obesity but without type 2 diabetes | Not children, people with diabetes or every clinical population |
| Treatment | Maximum tolerated weekly injectable tirzepatide 10 or 15 mg and semaglutide 1.7 or 2.4 mg | Not oral Wegovy, every dose, self-selected titration or a transition regimen |
| Duration and design | 72 weeks, randomized, open-label, controlled | Average trial response is not a personal forecast or lifetime comparison |
| Primary result | Mean percentage weight change under the trial estimand | Does not replace product-specific cardiovascular, kidney, liver, diabetes or safety evidence |
| Funding | Funded by Eli Lilly | Funding does not invalidate the trial, but belongs in interpretation and independent review |
Translate a trial into better questions—not a prescription
- Match the search to a market
Write the country and exact product first. A U.S. Mounjaro question and U.K. Mounjaro weight-management question use different label contexts.
- Check whether the person resembles the protocol
Diagnosis, age, diabetes status, prior treatment and clinical goal determine how directly SURMOUNT-5 applies.
- Keep averages and estimands visible
Use the trial's stated population and analysis rather than presenting one percentage as an expected result for every participant.
- Review outcomes beyond the scale
The prescriber may need glycemic, cardiovascular, kidney, liver, pregnancy, gastrointestinal, eye, gallbladder and other product-specific context.
- Verify the actual supply
Confirm prescription, licensed pharmacy, exact form, sealed package, storage and local instructions before any medicine question becomes an administration question.
How to interpret the comparison
This sequence separates molecule, approved use, trial population, dose studied and safety context. It does not decide which medicine is appropriate, convert doses or provide personal medicine-change instructions.
Compare the exact local label and the exact study population. Results from type 2 diabetes trials and obesity trials answer different questions and should not be treated as interchangeable brand claims.
Prescription comparison and safety principles
- Record country, exact brand, active ingredient, dosage form, strength and licensed pharmacy before comparing instructions.
- Do not copy milligrams, escalation steps, missed-dose rules or transition timing between semaglutide and tirzepatide.
- Keep a trial result attached to the studied population, injectable regimen, duration, estimand and funding; do not turn an average into a personal forecast.
- Verify local authorization and supply. A U.S. Mounjaro claim, U.K. Mounjaro claim and U.S. Zepbound claim are not interchangeable.
Seek urgent care for severe allergic symptoms, breathing difficulty, fainting or another emergency. Severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, symptoms of low glucose or another serious reaction need prompt advice under the exact local treatment plan. Do not combine, stop, switch or convert Wegovy and Mounjaro from this page.
Why your timeline may differ
Questions to ask before treatment
- Which exact brand, form, indication and country label apply?
- Does the cited trial match my diagnosis and treatment goal?
- Which other medicines and conditions change monitoring or risk?
- What does the trial measure, and which outcomes were not tested?
- Who will manage supply verification and any clinician-directed transition?
Wegovy and Mounjaro do not have one worldwide indication, form set, age range, device, price or reimbursement rule. Use the current product information where the medicine is supplied; this comparison is not a global formulary or personalized medicine ranking.
Find official checks for 12 marketsHow this guide was made
6 named sources support the main claims. Each link explains how it was used, with public agencies, professional bodies or primary research preferred.
AI may assist with research organization, drafting and translation, but it is not treated as a source or credential. Read the editorial standards.
Stage bars organize a relative sequence. Original editorial illustrations are conceptual and are not clinical measurements, outcome percentages or personal forecasts.
This version has editorial evidence review, not medical review attributed to a named clinician. It does not replace an individual assessment. Editorial accountability.
Sources
- FDA: Wegovy Prescribing Information (June 2026)
Current U.S. injection and tablet forms, product-specific indications, limitations, warnings and administration.
- DailyMed: U.S. Mounjaro Prescribing Information (April 2026)
Current U.S. injectable tirzepatide brand indication for type 2 diabetes, age scope, presentations, warnings and administration.
- SURMOUNT-5: Tirzepatide Compared with Semaglutide for Obesity
Open-label 72-week trial in 751 adults with obesity without diabetes comparing maximum tolerated weekly injectable tirzepatide and semaglutide regimens; funded by Eli Lilly.
- UK MHRA: GLP-1 Medicines for Weight Loss and Diabetes
Current U.K. brand and indication context, including licensed weight-management uses and prescription safeguards.
- UK MHRA: First GLP-1 Tablet for Weight Management
June 2026 authorization context for the Wegovy tablet in eligible U.K. adults; availability and prescribing remain separate questions.
- FDA: Concerns with Unapproved GLP-1 Drugs
Risks involving unapproved, compounded, fraudulent and counterfeit products, dosing errors and storage.
Frequently asked questions
What should I know about Wegovy vs Mounjaro?
Wegovy contains semaglutide and acts at the GLP-1 receptor; Mounjaro contains tirzepatide and acts at GIP and GLP-1 receptors. They are not interchangeable. In the United States, current Wegovy and Mounjaro labels serve different product-specific purposes, while the U.K. authorizes both brands for weight management in eligible people. SURMOUNT-5 directly compared selected injectable tirzepatide and semaglutide regimens in adults with obesity without diabetes, not every current form, brand claim or individual treatment choice.
Did SURMOUNT-5 compare Wegovy and Mounjaro for everyone?
No. It compared selected weekly injectable tirzepatide and semaglutide regimens for 72 weeks in adults with obesity without type 2 diabetes. The protocol does not cover every form, diagnosis, age, brand indication or personal treatment decision.
Why can the timeline differ from person to person?
Treatment type, depth, technique, anatomy, skin and tissue response, health history, medication, aftercare and complications can all change timing. The treating professional’s instructions take priority over a general guide.
When should I contact a professional?
Seek urgent care for severe allergic symptoms, breathing difficulty, fainting or another emergency. Severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, symptoms of low glucose or another serious reaction need prompt advice under the exact local treatment plan. Do not combine, stop, switch or convert Wegovy and Mounjaro from this page.
Compare the complete three-brand evidence map
Keep molecule evidence, U.S. brand labels, global authorizations and appearance questions in separate records.
Compare Zepbound and Wegovy Compare Wegovy and Ozempic Compare Mounjaro and OzempicExplore the complete GLP-1 beauty and body guide
Move between product identity, side-effect timing, facial documentation, hair-loss evidence, exercise safety and private tools without turning appearance into a diagnosis or prescription decision.
Open the GLP-1 topic hub Read the GLP-1 side-effects timelineRelated beauty guides
View BodyLiposuction Recovery Timeline: Week 1 to Month 6
A visual guide to bruising, swelling, activity limits and when body-contour results become easier to see after liposuction.
Read next BODYNonsurgical Body Contouring: Recovery and Results Timeline
Compare fat freezing, heat, ultrasound and magnetic body-contouring timelines, side effects, results and device-specific risks.
Read next BODYMounjaro Face: Facial Volume Changes, Evidence and Options
What ‘Mounjaro face’ means, why facial volume may change with substantial weight loss, what evidence can and cannot prove, and how to plan a qualified review.
Read nextThis guide is for general education only. It is not medical advice, diagnosis, a treatment recommendation or a prediction of individual results. BeautiNext is not a clinic. Seek care from an appropriately qualified professional.